JMAC
JMAC is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Sponsor Stemline Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A multicenter, open-label, prospective study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx® (bimekizumab)
Sponsor UCB Biopharma
- Start (EU)
- Not reported
- Latest update
- Estimated end
A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and subjects with thyroid eye disease (TED)
Sponsor Viridian Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for JMAC?
The 2026-10-09 snapshot links JMAC to 4 distinct CTIS trials. Recorded services include Manage prebooked patient travel/lodging, Participant Reimbursement/Stipend and travel bookings, Patient Reimbursement, reimburse self-booked travel expenses for participants only, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for JMAC?
The most frequently recorded therapeutic areas are Rheumatology, Dermatology, Immunology, Musculoskeletal. Recorded phases include Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to JMAC conducted?
The linked trials record locations in 16 countries, including Germany, Spain, France, Netherlands, Belgium. These are trial locations, not confirmed office locations or countries where JMAC delivered services.
What can this page tell me about JMAC's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under JMAC. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- JMAC